Is there a rationale for supplementing with vitamin D patients under treatment with allergen immunotherapy?

Figures & data

Table 1. Time dependent changes of clinical and laboratory parameters of SLIT and SLIT + VD3 treated patients.

	Time-dependent changes						VD3-dependent changes at 12-months
	AIT			AIT + VD3
Parameter	Baseline	12-months	p	Baseline	12-months	p	p
25-OH VD (ng/ml)	23.8 ± 5.7	25.2 ± 2.4	n.s.	20.1 ± 4.2	36.1 ± 2.8	#	§
ARIA	3.5 ± 0.6	1.5 ± 1.0	#	3.5 ± 0.6	0.9 ± 0.4	#	§
VAS	7.5 ± 1.7	3.2 ± 2.2	#	8.2 ± 1.1	1.7 ± 1.2	#	§
Total IgE (kU/L)	492 ± 529.4	385 ± 366.2	n.s.	692.3 ± 723.2	444.9 ± 366.8	#	n.s.
Dp IgE (kUA/L)	44.7 ± 29.0	55.3 ± 32.6	n.s.	60.0 ± 32.1	56.9 ± 36.4	n.s	n.s.
Df IgE (kUA/L)	35.4 ± 25.4	52.4 ± 31.6	n.s.	61.1 ± 32.9	40.9 ± 36.0	#	§
Patients taking antihistamines	28 (100%)	5 (17.8%)	#	12 (100%)	0 (0%)	#	§
Patients taking Nasal steroids	8 (28.7%)	1 (3.6%)	#	6 (50%)	0 (0%)	#	n.s

# p < 0.05 (baseline vs 12-months); § p < 0.05 (AIT + VD3 vs AIT); n.s. not significant. Wilcoxon signed rank test.

Figure 1. Incremental variation of the expression of activation marker HLA-DR on the effector memory subset of Tregs (CD127^neg/lowCD4^posCD25^posCD45RA^negCD39^posHLA-DR^pos) in the whole original cohort of AIT patients and the two sub-cohorts, either supplemented with VD3 or not.

Data availability statement

The data that support the findings of this study are available upon reasonable request.